Condition: NonSegmental Vitiligo · Sponsor: Incyte Corporation
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| University of Alabama At Birmingham-School of Medicine | Birmingham, Alabama, United States | Recruiting |
| Saguaro Dermatology | Phoenix, Arizona, United States | Recruiting |
| Phoenix Children'S Hospital | Phoenix, Arizona, United States | Recruiting |
| Omni Dermatology | Phoenix, Arizona, United States | Recruiting |
| Affiliated Dermatology | Scottsdale, Arizona, United States | Completed |
| Banner - University Medicine Multispecialty Services Clinic | Tucson, Arizona, United States | Recruiting |
| Premier Dermatology Clinical Trials Institute At Northwest Arkansas | Fayetteville, Arkansas, United States | Recruiting |
| Burke Pharmaceutical Research | Hot Springs, Arkansas, United States | Completed |
| Axon Clinical Research | Inglewood, California, United States | Recruiting |
| University of California Irvine | Irvine, California, United States | Recruiting |
| Vitiligo & Pigmentation Institute of Southern California | Los Angeles, California, United States | Recruiting |
| Dermatology Research Associates | Los Angeles, California, United States | Recruiting |
+ 86 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06548360